Pharmacogenetics of Pain Management in Zimbabwean Patients With Sickle Cell Disease

References

• Sanyaolu A , AgiriE , BertramCet al. Current modalities of sickle cell disease management. Blood Sci.2(4), 109–116 (2020).
   PubMedGoogle Scholar
• Kavanagh PL , FasipeTA , WunT. Sickle cell disease: a review. JAMA328(1), 57–68 (2022).
   PubMed Web of Science ®Google Scholar
• Farrell AT , PanepintoJ , CarrollCPet al. End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain. Blood Adv.3(23), 3982–4001 (2019).
   PubMed Web of Science ®Google Scholar
• Makani J , Ofori-AcquahSF , NnoduO , WonkamA , Ohene-FrempongK. Sickle cell disease: new opportunities and challenges in Africa. Sci. World J.2013, 193252 (2013).
   Web of Science ®Google Scholar
• Somogyi AA , BarrattDT , CollerJK. Pharmacogenetics of opioids. Clin. Pharmacol. Ther.81(3), 429–444 (2007).
   PubMed Web of Science ®Google Scholar
• Orhurhu MS , ChuR , ClausLet al. Neuropathic pain and sickle cell disease: a review of pharmacologic management. Curr. Pain Headache Rep.24(9), 52 (2020).
   PubMed Web of Science ®Google Scholar
• Crews KR , MonteAA , HuddartRet al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin. Pharmacol. Ther.110(4), 888–896 (2021).
   PubMed Web of Science ®Google Scholar
• Matic M , NijenhuisM , SoreeBet al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). Eur. J. Hum. Genet.30(10), 1105–1113 (2022).
   PubMed Web of Science ®Google Scholar
• Willmann S , EdgintonAN , CoboekenK , AhrG , LippertJ. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clin. Pharmacol. Ther.86(6), 634–643 (2009).
   PubMed Web of Science ®Google Scholar
• Lloyd RA , HothamE , HallC , WilliamsM , SuppiahV. Pharmacogenomics and patient treatment parameters to opioid treatment in chronic pain: a focus on morphine, oxycodone, tramadol, and fentanyl. Pain Med.18(12), 2369–2387 (2017).
   PubMed Web of Science ®Google Scholar
• Thorn CF , KleinTE , AltmanRB. Codeine and morphine pathway. Pharmacogenet. Genomics19(7), 556–558 (2009).
   PubMed Web of Science ®Google Scholar
• Whirl-Carrillo M , HuddartR , GongLet al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther.110(3), 563–572 (2021).
   PubMed Web of Science ®Google Scholar
• Whirl-Carrillo M , McDonaghEM , HebertJMet al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther.92(4), 414–417 (2012).
   PubMed Web of Science ®Google Scholar
• Reizine N , DanaheyK , SchiererEet al. Impact of CYP2D6 pharmacogenomic status on pain control among opioid-treated oncology patients. Oncologist26(11), e2042–e2052 (2021).
   PubMed Web of Science ®Google Scholar
• Snyder D . Pain: clinical manual for nursing practice. By Margo McCaffery and Alexandra Beebe. St. Louis: C.V. Mosby Company, 1989, 353 pp. Cancer Nurs.15(3), 211 (1992).
   Web of Science ®Google Scholar
• Wilkie DJ , JohnsonB , MackAK , LabotkaR , MolokieRE. Sickle cell disease: an opportunity for palliative care across the life span. Nurs. Clin. North Am.45(3), 375–397 (2010).
   PubMed Web of Science ®Google Scholar
• Platt OS , ThoringtonBD , BrambillaDJet al. Pain in sickle cell disease. N. Engl. J. Med.325(1), 11–16 (1991).
   PubMed Web of Science ®Google Scholar
• Ross JR , RutterD , WelshKet al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J.5(5), 324–336 (2005).
   PubMed Web of Science ®Google Scholar
• Kuguyo O , MisiFD , ChibondaS , MatimbaA , NhachiC , TsikaiN. Pain management strategies among cervical cancer patients in Zimbabwe. Pain Manag.11(6), 715–729 (2021).
   PubMed Web of Science ®Google Scholar
• Osunkwo I , AndemariamB , MinnitiCPet al. Impact of sickle cell disease on patients’ daily lives, symptoms reported, and disease management strategies: results from the international Sickle Cell World Assessment Survey (SWAY). Am. J. Hematol.96(4), 404–417 (2021).
   PubMed Web of Science ®Google Scholar
• Mbavha BT , KanjiCR , StadlerNet al. Population genetic polymorphisms of pharmacogenes in Zimbabwe, a potential guide for the safe and efficacious use of medicines in people of African ancestry. Pharmacogenet. Genomics32(5), 173–182 (2022).
   PubMed Web of Science ®Google Scholar
• Gaedigk A , SimonSD , PearceRE , BradfordLD , KennedyMJ , LeederJS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther.83(2), 234–242 (2008).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J , KeulenJT , BauerS , RootsI , BrockmöllerJ. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J. Clin. Psychopharmacol.28(1), 78–83 (2008).
   PubMed Web of Science ®Google Scholar
• Smith HS . The metabolism of opioid agents and the clinical impact of their active metabolites. Clin. J. Pain27(9), 824–838 (2011).
   PubMed Web of Science ®Google Scholar
• Foster A , MobleyE , WangZ. Complicated pain management in a CYP450 2D6 poor metabolizer. Pain Pract.7(4), 352–356 (2007).
   PubMedGoogle Scholar
• Jannetto PJ , BratanowNC. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management. Pharmacogenomics10(7), 1157–1167 (2009).
   PubMed Web of Science ®Google Scholar
• Fladvad T , KlepstadP , LangaasMet al. Variability in UDP-glucuronosyltransferase genes and morphine metabolism: observations from a cross-sectional multicenter study in advanced cancer patients with pain. Pharmacogenet. Genomics23(3), 117–126 (2013).
   PubMed Web of Science ®Google Scholar
• Li J , MenardV , BenishRLet al. Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment. Pharmacogenomics13(5), 555–570 (2012).
   PubMed Web of Science ®Google Scholar
• Sadhasivam S , KrekelsEH , ChidambaranVet al. Morphine clearance in children: does race or genetics matter? J. Opioid Manag. 8(4), 217–226 (2012).
   PubMedGoogle Scholar
• Ning M , TaoY , HuXet al. Roles of UGT2B7 C802T gene polymorphism on the efficacy of morphine treatment on cancer pain among the Chinese Han population. Niger. J. Clin. Pract.22(10), 1319–1323 (2019).
   PubMed Web of Science ®Google Scholar
• De Gregori M , DiatchenkoL , IngelmoPMet al. Human genetic variability contributes to postoperative morphine consumption. J. Pain17(5), 628–636 (2016).
   PubMed Web of Science ®Google Scholar
• Gong L , StamerUM , TzvetkovMV , AltmanRB , KleinTE. PharmGKB summary: tramadol pathway. Pharmacogenet. Genomics24(7), 374–380 (2014).
   PubMed Web of Science ®Google Scholar